Working… Menu

Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00794430
Recruitment Status : Completed
First Posted : November 20, 2008
Last Update Posted : June 3, 2016
Information provided by (Responsible Party):
Vernalis (R&D) Ltd

Brief Summary:
Randomised, double-blind, placebo-controlled, parallel group, multicentre study of oral doses of V3381, titrated to effect. A 2-week single-blind run-in period will be followed by a 13 week double-blind titration and maintenance phase. Doses will be titrated up in 100 mg bid increments every one or two weeks, starting from 100 mg bid. A 2 week follow-up period will conclude patient participation in the study.

Condition or disease Intervention/treatment Phase
Diabetic Peripheral Neuropathic Pain Drug: V3381 Drug: Placebo Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 161 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for up to 13 Weeks in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Study Start Date : December 2008
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Arm Intervention/treatment
Experimental: V3381
V3381: titrated from 100 mg bid to maximum 400 mg bid over 4 weeks followed by maintenance phase at highest tolerated dose. Total duration of treatment 13 weeks.
Drug: V3381
100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
Other Name: Indantadol

Placebo Comparator: Placebo
Placebo to match V3381, 100 mg, given according to the same regimen.
Drug: Placebo
Capsule, bid, for 13 weeks

Primary Outcome Measures :
  1. Investigate the safety and tolerability of V3381 in patients with diabetic neuropathic pain at doses of up to 400 mg bid [ Time Frame: 17 weeks ]

Secondary Outcome Measures :
  1. Determine the efficacy of V3381 in the treatment of diabetic peripheral neuropathic pain at does of up to 400 mg bid [ Time Frame: 17 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed written informed consent
  2. Male or female aged 18 - 75 (18-65 Czech Republic)
  3. Diagnosis of diabetes mellitus
  4. No change in diabetes medications within 4 weeks before screening
  5. Daily pain attributed to diabetic neuropathy present for at least 6 months immediately prior to study entry
  6. Presents with pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes mellitus. Pain must have begun in the feet, with relatively symmetrical onset. Diagnosis confirmed by a score of at least 2 on Section B of the MNSI
  7. Judged to be reliable and agree to keep all appointments required by the protocol
  8. Females should be of non child-bearing potential (i.e. surgically sterilized or >1 year post-menopause). Male subjects who are sexually active with a female partner of child bearing potential must agree to use a barrier method of contraception (eg condom, diaphragm or cervical cap in the female female partner) for the duration of the study (until the follow up visit)

    Additionally, at the baseline visit:

  9. A mean average pain intensity of at least 4, but less than or equal to 9, on an 11 point Likert NPRS recorded twice daily during the two week placebo run-in; any patient who experiences a >30% decrease in the mean pain score compared to Day -14 during placebo run-in will be excluded, regardless of whether their final score is >4
  10. Full completion of daily diaries for at least 11 of the days up to Day -1
  11. Compliance in taking placebo run-in medication twice daily for at least 11 of the days up to Day -1

Exclusion Criteria:

  1. Any clinically significant neurologic disorders (except DPNP)
  2. Any clinically significant or unstable medical or psychiatric condition that would affect the patient's ability to participate in the study
  3. Prior renal transplant, current renal dialysis
  4. Pernicious anemia
  5. Untreated hypothyroidism
  6. Amputations or persistent ulceration due to diabetes mellitus
  7. Any cardiovascular condition that would contraindicate the use of sympathomimetic amines
  8. Uncontrolled hypertension
  9. Known or at high risk of HIV infection
  10. Any anticipated need for surgery during the study
  11. Increased risk of seizures (defined as a history of seizure disorder (including alcoholic seizures), family history of seizures and history of head trauma that resulted in loss of consciousness or concussion).
  12. Any malignancy in the past 2 years (except basal cell carcinoma)
  13. Pain that cannot be clearly differentiated from, or conditions that interfere with, the assessment of diabetic neuropathic pain
  14. Use of anticonvulsants, antidepressants (particularly MAO inhibitors), or prescription membrane-stabilizing agents, including topical therapies. Patients currently taking drugs in these classes may have them discontinued prior to entry into the placebo run-in period.
  15. Use of opioids, especially meperidine (pethidine)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00794430

Layout table for location information
United States, Arkansas
Clinical Trials Inc
Little Rock, Arkansas, United States, 72205
United States, Florida
Renstar Inc
Ocala, Florida, United States, 34471
Radiant Research Inc
St petersburg, Florida, United States, 33781
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, Nevada
Advanced Biomedical Research of America
Las Vegas, Nevada, United States, 89123
United States, Ohio
Radiant Research Inc
Cincinnati, Ohio, United States, 45249
Neurology & Neuroscience Center of Ohio
Toledo, Ohio, United States, 43623
United States, Texas
dgd Research
San Antonio, Texas, United States, 78229-4801
Endeavor Clinical Trials
San Antonio, Texas, United States, 78229
LMC Endocrinology
Thornhill, Canada, L4J 8L7
LMC Endocrinology
Toronto, Canada, M4R 2G4
Czech Republic
ResTrial s.r.o.
Praha, Prague, Czech Republic, 180 00
Private Clinic
Brno, Czech Republic, 612 00
Nemocnice Ceske Budejovice
Ceske Budejovice, Czech Republic, 370 87
Private Clinic
Holesov, Czech Republic, 769 01
Private Clinic
Hranice, Czech Republic, 753 01
Smetanovy sady
Karlovy Vary, Czech Republic, 360 01
Neurologicke oddeleni
Pardubice, Czech Republic, 53 002
Private Clinic, Michnova 1622/4
Prague, Czech Republic, 149 00
Lekarsky dum Ormiga
Zlin, Czech Republic, 760 01
Diabetology Center
Zlin, Czech Republic, 762 75
United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom, EH16 4SA
Ipswich Hospital NHS Trust
Ipswich, Suffolk, United Kingdom
Barnsley Hospital
Barnsley, United Kingdom, S75 2EP
MAC UK Neuroscience
Blackpool, United Kingdom, FY2 0JH
Addenbrookes Hospital
Cambridge, United Kingdom, CB2 0QQ
Colchester Hospital University NHS Foundation Trust
Colchester, United Kingdom, CO4 5JL
Pallium Research Group (Seacroft Hospital)
Leeds, United Kingdom, LS14 6UH
St John's Hospital
Livingston, United Kingdom, EH54 6PP
Barts and The London NHS Trust
London, United Kingdom, EC1A 7BE
Royal Hallamshire Hospital
Sheffield, United Kingdom, S10 2JF
Sponsors and Collaborators
Vernalis (R&D) Ltd
Layout table for investigator information
Principal Investigator: Christine Sang Brigham and Women's Hospital

Layout table for additonal information
Responsible Party: Vernalis (R&D) Ltd Identifier: NCT00794430     History of Changes
Other Study ID Numbers: V3381-2DPNP-02
First Posted: November 20, 2008    Key Record Dates
Last Update Posted: June 3, 2016
Last Verified: January 2015
Keywords provided by Vernalis (R&D) Ltd:
Diabetic peripheral neuropathic pain.
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases